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Ghanaa b s t r a c t
Background: Cervical cancer is responsible for around one-quarter of all cancer deaths among Ghanaian
women. Between 2013 and 2015, Ghana conducted a pilot of HPV vaccination among 10–14-year-old
girls in four regions; however, the country has yet to introduce the vaccine nationally. This study pro-
jected the cost-effectiveness and budget impact of adding HPV vaccination into Ghana’s national immu-
nization program.
Methods: We used a proportional outcomes model (UNIVAC, version 1.4) to evaluate the cost-
effectiveness of introduction with bivalent (CervarixTM) and quadrivalent (Gardasil) vaccines from gov-
ernment and societal perspectives. Vaccine introduction was modeled to start in 2022 and continue over
ten birth cohorts using a combined delivery strategy of school (80%) and community outreach (20%). We
modeled vaccination in a single age cohort of 9-year-old girls vs. a multi-age cohort of 9-year-old girls
(routine) and 10–14-year-old girls (one-time campaign) compared to no vaccination. Health outcomes
included cervical cancer cases, hospitalizations, deaths, and disability-adjusted life years (DALYs). We
applied a discount rate of 3% to costs and outcomes. All monetary units are reported in USD 2018.
Results: National HPV vaccination in Ghana was projected to be cost-effective compared to no vaccina-
tion in all scenarios evaluated. The most cost-effective and dominant strategy was vaccination among
9-year-old girls, plus a one-time campaign among 10–14-year-old with the bivalent vaccine ($158/
DALY averted from the government perspective; 95% credible range: $19–$280/DALY averted).
Projected average annual costs of the vaccine program ranged from $11.2 to $15.4 M, depending on strat-
egy. This represents 11–15% of the estimated total immunization costs for 2022 ($100,857,875 based on
Ghana’s comprehensive Multi-Year Plan for Immunization, 2020–2024).
Discussion: Our model suggests that introducing HPV vaccination would be cost-effective in Ghana under
any strategy when willingness-to-pay is at least 40% GDP per capita ($881). Inclusion of a one-time catch-
up campaign is shown to create greater value for money than routine immunization alone but would
incur greater program costs.
 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
In sub-SaharanAfrica (SSA), cervical cancer is the leading causeof
death due to cancer in women [1]. Despite the preventable, detect-
able, and treatable nature of cervical cancer – and global progress
toward reducing disease burden in high-income countries – trend
data from cervical cancer registries in SSA suggest that overall inci-dence in the region has been increasing over time [2]. In 2018, the
highest age-standardized incidence of cervical cancer globally was
recorded in 15 countries2 in SSA where national vaccination, screen-
ing, and treatment programs are limited and highHIV prevalence con-
tributes to accelerated risk for cervical cancer [1–3]. InGhana, the age-
standardized incidence rate of cervical cancer is 32.9 per 100,000
women and age-standardized mortality rate is 23.0 per 100,000Lesotho,
bique.
uction
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tively [1]. Cervical cancer is responsible for approximately one-
quarter of all cancer deaths among Ghanaian women [1].
Given the promising available strategies to prevent, detect, and
treat cervical cancer, the World Health Organization (WHO) has
called for the elimination of cervical cancer as a public health pri-
ority [4]. Disease prevention through vaccination against human
papillomavirus (HPV) is a core pillar of the WHO strategy for elim-
ination [4]. As of 2020, three vaccine products have received WHO
prequalification for administration: the CervarixTM bivalent, Gar-
dasil quadrivalent, and Gardasil-9 nonavalent HPV vaccines.3
These vaccines have been demonstrated to be safe and efficacious
with no evidence of waning immunity [5–8]. All prevent nearly
100% of infections due to HPV types 16 and 18 that cause most cer-
vical cancers, as well as cervical intraepithelial neoplasia (CIN), vul-
var and vaginal intraepithelial neoplasia due to HPV types in the
vaccines [9]. The Cervarix bivalent vaccine cross-protects against a
significant portion of CIN due to non-vaccine HPV types 31, 33,
and 45, while the Gardasil quadrivalent and nonavalent vaccines
protect against infections due to HPV types 6 and 11 responsible
for genital warts [9,10]. The nonavalent provides further direct pro-
tection against HPV types 31, 33, 45, 52, and 58 [9].
The WHO currently recommends HPV vaccination for girls 9–
14 years old in all countries [11]. As of June 2020, 107WHOmember
states and 21 non-member independent territories—primarily high-
or upper-middle-income—have incorporated HPV vaccination into
their national immunization programs [12]. In low- and middle-
income countries (LMICs), incorporation into national immunization
programs has been slower and often initiated as pilot introductions
or vaccine demonstration projects with variable coverage [13,14].
InGhana, HPV vaccinationwas piloted through a demonstration pro-
gram in fourdistricts from2013 to2015 among in-school andout-of-
school girls aged 10–14 years via a three-dose schedule with the
quadrivalent vaccine [15]. Subsidized vaccine support is available
fromGavi, the Vaccine Alliance for HPV vaccine introduction in eligi-
ble LMICs, including Ghana; however, the country’s national immu-
nization technical advisory group (NITAG) has yet to recommend
introduction in the national immunization schedule.
Potential value for money and financial sustainability, in addi-
tion to health impact, are critical components for decision-
makers considering new vaccine introduction, product selection,
and delivery strategies [16]. Several studies have evaluated the
cost-effectiveness of HPV vaccination of girls globally and suggest
that it is likely to be a cost-effective public health investment [17–
19]. However, there is limited data available on the local costs and
cost-effectiveness of national HPV vaccination in Ghana [15]. This
study evaluated the projected cost-effectiveness and budget
impact of adding HPV vaccine into Ghana’s national immunization
program through a combined delivery strategy of school-based
vaccinations and community outreach to inform the country’s vac-
cine introduction decision.2. Materials and methods
2.1. Analytic framework and model
We used the UNIVAC tool (version 1.4) to assess the financial,
economic and health impacts of various national HPV vaccination3 CervarixTM (bivalent product by GlaxoSmithKline Biologicals), Gardasil (quadri-
valent product by Merck/MSD), and Garadisil-9 (nonavalent product by Merck/MSD)
were the only three WHO prequalified HPV vaccines on the market at the time this
analysis was conducted. WHO prequalification is expected in 2021 for the bivalent
product Cecolin by Xiamen Innovax Biotech Co. Limited. Cecolin has demonstrated
high safety and efficacy against HPV-16/18-associated cervical intraepithelial
neoplasia in clinical trials [42].
2
scenarios, each compared to no vaccination in Ghana and among
the competing vaccination strategies. UNIVAC is a transparent pro-
portional outcomes model that evaluates vaccine impact and cost-
effectiveness of several childhood vaccines, including HPV, with
flexibility to examine the impact of different vaccine products
and programmatic choices on costs and health outcomes [20].
The model simulates the target population over the individual’s
lifetime horizon, applies age-specific cervical cancer rates to esti-
mate the expected disease burden with and without vaccination,
and assigns outcomes to each cohort of girls. This simple approach
does not involve recalculating health states at regular time steps
and is static rather than dynamic, i.e., it does not account for poten-
tial feedback/interactions between health states over time. Health
outcomes include cervical cancer cases stratified by stage, hospital-
izations, deaths, and disability-adjusted life years (DALYs). Costs
include vaccine price, vaccine introduction and delivery costs,
and costs of cervical cancer treatment by stage. Incremental costs
and health outcomes are then combined into an average or incre-
mental cost-effectiveness ratio (cost per DALY averted).
Plausible HPV vaccine introduction strategies of interest in
Ghana were developed with input from key stakeholders, including
the Ghana Ministry of Health Expanded Program on Immunization
(EPI). Vaccine introduction was modeled to start in 2022 and con-
tinue over ten consecutive birth cohorts using a combined delivery
strategy of school-based vaccinations (80%) and community out-
reach (20%). We modeled national HPV immunization with either
the Cervarix bivalent or Gardasil quadrivalent vaccine compared
to no vaccination in two potential target populations: 1) a single
age cohort of 9-year-old girls (routine only), and 2) a multi-age
cohort (MAC) of 9-year-old girls (routine) and 10–14-year-old girls
(one-time campaign). Under all scenarios, we assumed that the
second dose would be administered six months after initial vacci-
nation, accounting for minimal coverage decreases between dose
one and two. The base case analysis was modeled as introduction
among 9-year-old girls (routine only) using the quadrivalent
vaccine.
Costs and health outcomes for each cohort were then simulated
over the lifetime horizon based on population size and life expec-
tancy by age from the United Nations Population Division 2017
Revision [21], age-specific disease incidence and mortality
(Fig. 1), vaccine coverage, and vaccine efficacy. We used a pooled
odds ratio from the FUTURE and PATRICIA trials as our base case
estimate for vaccine efficacy [10]. We also considered the underly-
ing cross-protection provided by each vaccine against non-vaccine
types in our sensitivity analyses by incorporating estimates of
underlying HPV genotype prevalence in Ghana and cross-
protection against each genotype with each vaccine [10,22–24]. A
weighted vaccine efficacy was calculated to account for efficacy
against specific types.
Expected costs of vaccine program introduction and vaccine
delivery were derived from a 2014 cost analysis conducted using
the WHO C4P costing tool alongside Ghana’s HPV vaccination
demonstration project (data not published). This report estimated
delivery costs of $9.65 per dose across multiple cohorts. Delivery
cost offsets via Gavi subsidies were also included. Recent (2020)
guidance from Gavi indicates that operations (Ops) grants for
HPV delivery are provided to support campaign operational costs,
and amounts are based on the country’s Gavi phase. Initial self-
financing countries receive $0.65 per targeted person, preparatory
transition phase countries receive $0.55 per targeted person, and
accelerated transition countries receive $0.45 per targeted person
[25]. Gavi vaccine introduction grants (VIGs) subsidize the costs
of routine HPV delivery through either a lump sum of $100,000
or $2.40 per targeted girl, whichever is higher [25]. For this analy-
sis, subsidies to the government and vaccine price for each year






















Age groups (years) 
Local Incidence Regional Incidence Distant Incidence
Total Incidence Mortality
†Esmates were based on data from Globocan 2018 [42]. Simplified definions were used for 
invasive cancer categories based on FIGO staging [43]. Local Invasive cancer was defined as FIGO 
Stage 1a1, 1a2, 1b1, 1b2, 2a1, 2a2. Regional invasive cancer was defined as FIGO Stages 2b1, 2b2, 
3a1, 3a2, 3b1, 3b2. Distant invasive cancer was defined as FIGO Stage 4a-4b.
Fig. 1. Age-specific disease burden by stage in Ghana (2018).
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year (2022) and associated co-share amount per dose, with Gavi
supplementing any remaining amount of the vaccine tender
[25,26]. Therefore, introduction and operational cost subsidies
from Gavi assumed a VIG of $2.40 per girl for routine immuniza-
tion in the first year and an Ops grant of $0.45 per girl for those
in the MAC [25].
Local administrative and clinical experts at five health facilities
(which together manage most of cervical cancer cases in Ghana)
were consulted to ascertain direct medical costs of cervical cancer
treatment and typical treatment for cervical cancer by stage. Facil-
ities included three public tertiary hospitals (Korle Bu Teaching
Hospital in Accra, Komfo Anokye Teaching Hospital in Kumasi,
Tamale Teaching Hospital in Tamale), one public secondary hospi-
tal (Greater Accra Regional Hospital, Accra), and one mission hos-
pital (Battor Catholic Hospital, Battor). Information from experts
was supplemented by typical treatment strategies outlined by
the Federation of International Gynecology and Obstetrics and
existing literature on cervical cancer by stage and access to care
in Ghana [27–29]. Typical care components captured as part of
treatment costs were consult and diagnosis, staging, and treatment
strategies for invasive cancer, including radical and simple hys-
terectomy, chemotherapy, radiotherapy, concomitant delivery of
chemo-radiation, and palliation. All women receiving treatment
were assumed to have one follow-up visit, including consult,
histopathology, and lab testing (full blood count and sickling test).
Treatment strategies and their unit costs were allocated to local,
regional and distant cancer proportionally, based on staging inci-
dence and probability of treatment.3
Societal-level treatment costs included direct medical costs,
plus opportunity costs of women’s time for procedures (including
convalescence if they had hospital stays or recovery time), time
waiting for test results (if provided on the same day as procedures),
and time costs associated with travel to/from facility visits. The
amount of time women spent traveling to/from facilities for cervi-
cal cancer treatment was estimated based on a 2013 study pre-
senting average travel times to/from facilities in Ghana for
maternity care [30]. For opportunity costs of women’s time, we
applied the Ghana 2018 minimum wage, reported as 10.65 Ghana-
ian cedis per day (USD 2018 $2.32) [31]. We valued the time of
women at minimum wage regardless of working status. Due to
data limitations, we did not include costs for meals purchased,
accommodations, fuel or transport fares, or caregiver costs.
We applied a discount rate of 3% to costs and health outcomes.
All monetary units are reported in USD 2018. We estimated costs
and cost-effectiveness ratios from government and societal per-
spectives. We compare cost-effectiveness ratios to GDP per capita
as a proxy as Ghana does not have an established cost-
effectiveness threshold. Key input parameters are described in
Table 1.
2.2. Uncertainty analyses
We conducted one-way sensitivity analyses for each scenario to
assess the impact of individual parameter uncertainty on model
results, presented as tornado diagrams. We ran probabilistic sensi-
tivity analyses to assess the impact of combined parameter uncer-














Base case: Coverage estimate from 2014 Ghana HPV demonstration project costing.
Assume 1% drop in coverage based on demonstration attrition between doses.
Ranges: First/final dose coverage estimates for LMICs [44]
Two-dose vaccine efficacy against HPV
16 and 18b
94% 92–97% Pooled odds ratio from FUTURE and PATRICIA trials [10]
Two-dose cross-protection by HPV
type, quadrivalent
Type 31: 70% 32.1–88.2% [10]



















Base case: Gavi price per dose [45];
Range: ±50% of base case





N/A Annual co-financing share per dose was estimated based on Ghana’s 2019 starting
fraction of 32%.
Vaccine supplies, price per dose $0.08 $0.07–$0.09 2014 Ghana HPV demonstration costing
Wastage 5% 4–6% 2014 Ghana HPV demonstration costing
Average health system cost per dosed $9.65 Varies annually,
range from $4.67-
$16.58
Calculation; Low range = 50% of base case. High range = 120% of base case.
Average cervical cancer treatment cost









Calculation; Low range = 50% of base case. High range = 200% of base case.
Average cervical cancer treatment cost









Calculation; low range = 50% of base case; high range = 200% of base case.









[46] Diagnosis and primary therapy phase of cervical cancer
[46] Metastatic phase of cervical cancer
[46] Terminal phase of cervical cancer










Calculated based on local and international data
a Year-over-year changes in cohort size and average life-expectancy were obtained from annual UNPop 2017 projections. Average life-expectancy for the 2022 birth cohort
was 64.3 years [21].
b For those who receive only a single dose, we assume half of the two dose efficacy.
c Year-over-year co-financing projections were estimated based on Ghana’s 2019 starting fraction (32.1%) and expected annual transition phase (Year 2 of Preparatory
Transition Phase in 2019). Ghana is anticipated to become fully self-financing by 2026 at which point the MOH would be responsible for 100% of the Gavi vaccine price.
d Health systems cost was derived from 2014 C4P costing data collected during the Ghana HPV demonstration project and based on 3-dose schedule. Analysis was adapted
for a 2-dose delivery schedule. Year 1 estimates assume a Gavi vaccine introduction grant (VIG) subsidy of $2.40 per person for single-aged cohort and operations grant (Ops)
subsidy of $0.45 per person for the multi-aged cohort doses provided. Assumes 80% of girls are reached through school-based delivery and 20% are reached through
community outreach. On average, school-based delivery was estimated at $9.05 and community outreach at $10.44 per dose. Community outreach costs were higher
primarily due to additional transportation costs. Ranges were calculated for each annual delivery cost as +/- 20% of base case annual estimate.
e Estimated based on typical patient flow by cervical cancer stage and expected proportion of women in each stage [28,29]. Costs were based fee schedule information for
typical treatment services from five facilities and supplemented with literature and expert opinion. Assumed one course of treatment per cervical cancer case. Data on loss to
follow-up after treatment referral was sparse. As such, we address potential differences in average treatment costs per case due to loss to follow-up through inclusion of wide
sensitivity ranges.
f Productivity losses and opportunity costs of missed wages were estimated based on the 2018 daily minimum wage in Ghana (10.65 cedis daily wage in 2018) [31].
g Base case average duration of illness was estimated based on SurvCan data from India [47] using the Declining Exponential Approximation of Life Expectancy method to
convert five-year survival rates into average duration of life expressed in years [48]. Low range was estimated based on limited 5-year survival data from Ghana [29] using
DEALE methodology and life expectancy. High range was estimated as +20% of base case estimate due to limited upper bound data.
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ranges over 10,000 Monte Carlo simulations. Ninety-five percent
uncertainty intervals represent the 2.5th and 97.5th percentiles
of probabilistic simulations; for each probabilistic simulation,
parameters were drawn from a distribution with a mean equal to
the point estimate and range equal to the low and high values of
the uncertainty range. In the absence of information about the4
shape of each distribution, a simple PERT-Beta distribution was
assumed for all parameters [32].
3. Results
National HPV vaccination in Ghana was projected to be cost-
effective compared to no vaccination in all scenarios evaluated.
Table 2
Population health impact of HPV vaccination compared to no vaccination by delivery











Local invasive 88,107 28,381 59,726
Regional invasive 69,639 22,432 47,208
Distant invasive 18,307 5,897 12,410
Deaths 105,933 34,123 71,811
DALYs 345,103 111,163 233,940
Bivalent vaccine, routine immunization of 9-year-old girls, plus one-time




Local invasive 121,798 39,233 82,565
Regional invasive 96,269 31,010 65,259
Distant invasive 25,308 8152 17,156
Deaths 147,109 47,386 99,723
DALYs 500,118 161,096 339,023




Local invasive 88,107 49,359 38,748
Regional invasive 69,639 39,013 30,626
Distant invasive 18,307 10,256 8,051
Deaths 105,933 59,345 46,588
DALYs 345,103 193,332 151,772
Quadrivalent vaccine, routine immunization of 9-year-old girls, plus one-time




Local invasive 121,798 68,233 53,565
Regional invasive 96,269 53,931 42,338
Distant invasive 25,308 14,178 11,130
Deaths 147,109 82,412 64,696
DALYs 500,118 280,173 219,945
Table 3
Discounted costs of HPV vaccination compared to no vaccination by delivery scenario







Bivalent vaccine, routine immunization of 9-year-old girls





Health care costs (societal
perspective)
$52,564,378 $16,931,783 -$35,632,595
Bivalent vaccine, routine immunization of 9-year-old girls, plus one-time
campaign among 10–14-year-old girls





Health care costs (societal
perspective)
$76,381,806 $24,603,736 -$51,778,070
Quadrivalent vaccine, routine immunization of 9-year-old girls





Health care costs (societal
perspective)
$52,564,378 $29,447,292 -$23,117,086
Quadrivalent vaccine, routine immunization of 9-year-old girls, plus one-time
campaign among 10–14-year-old girls





Health care costs (societal
perspective)
$76,381,806 $42,790,145 -$33,591,661
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least costly and most impactful scenario and thus dominated all
other options. For the base case scenario modeling introduction
among 9-year-old girls with the quadrivalent vaccine, vaccination
was projected to avert 77,426 total cervical cancer cases, 46,588
cervical cancer deaths, and 151,772 DALYs compared to no vacci-
nation over 10 birth cohorts. Vaccination under this scenario was
expected to incur $74,987,137 more in discounted costs from the
government perspective and $74,111,553 more from the societal
perspective compared to no vaccination. The higher costs with vac-
cination were primarily associated with new program costs
incurred for vaccine introduction and delivery (net $97,228,640
incurred) and offset by downstream costs of cervical cancer treat-
ment averted due to primary prevention of disease through vacci-
nation (net $22,241,503 and $23,117,086 averted from the heath
system and societal perspectives, respectively). The cost per DALY
averted was estimated to be $494 from the government perspec-
tive and $488 per DALY averted from the societal perspective for
this scenario.
The most cost-effective strategy modeled was vaccination
among 9-year-old girls, plus a one-time campaign among 10–14-
year-olds with the bivalent vaccination ($158/DALY averted from
the government perspective and $152/DALY averted from the soci-
etal perspective). This strategy was dominant because it had the
lowest cost and larger effects compared all other strategies. Results
for all scenarios evaluated relative to no vaccination are presented
in Table 2 (health outcomes) and Table 3 (costs). Incremental costs,
DALYs averted and cost per DALY averted compared to the domi-
nant strategy are presented in Appendix Table 1.
One-way sensitivity analyses show that the model outcomes
were most influenced by variation in cervical cancer treatment
costs and disease event rates, followed by vaccine efficacy, incre-5
mental health system costs per dose, vaccine price per dose, and
coverage rates (Fig. 2). Across scenarios and perspectives, when
varying individual parameters for uncertainty impacts, the cost
per DALY averted for vaccination among girls ranged from cost-
saving to $862. This represents up to 39% of Ghana’s gross domes-
tic product (GDP) per capita of $2202 (USD$ 2018). Results from
the probabilistic sensitivity analyses determined 95% credible
ranges (CR) around the ratios for each scenario, providing a range
of $19–$739 from the government perspective and $18–$733 from
the societal perspective (Table 4). This represents 0.8–34% of GDP
per capita. Ghana, like many countries, does not have established
cost-effectiveness thresholds for health interventions, including
vaccination. However, as shown in the cost-effectiveness accept-
ability curve in Fig. 3, results from the probabilistic sensitivity
analysis found that HPV vaccination would be cost-effective com-
pared to no vaccination in 100% of simulations at a willingness-
to-pay threshold of $881 per DALY averted. A threshold of $881
per DALY averted corresponds to 40% of GDP per capita.
Projected average annual undiscounted financial costs of the
vaccine program over ten birth cohorts range from $11.2-$15.4 M,
depending on strategy (Appendix Table 2). This represents 11–15%
of the projected total immunization costs for 2022 based on Gha-
na’s comprehensive Multi-Year Plan (cMYP) for immunization
(2020–2024). Projected first-year costs were higher for scenarios
with a one-time MAC catch-up in addition to the routine immu-
nization single-age cohort compared to scenarios with a single-
age cohort only. In our scenario of vaccine introduction in 2022,
costs for vaccination with a MAC plus routine immunization were
$54,924,813 with the bivalent vaccine and $54,876,175 with the
quadrivalent vaccine, representing approximately 54% of Ghana’s
cMYP projected annual costs for the total immunization program
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Quadrivalent vaccine, roune cohort + MAC (government perspecve) 
Low Input
High Input
Fig. 2. One-way sensitivity analyses for vaccine selection and delivery strategy.
E. Vodicka, J. Nonvignon, K.O. Antwi-Agyei et al. Vaccine xxx (xxxx) xxxaged routine immunization were projected to be much lower at
$12,217,202 with the bivalent vaccine and $12,168,564 with the
quadrivalent vaccine. Subsequent year-over-year costs across sce-
narios ranged from $9,515,968 to $15,363,686. The high outlay that
we see in the first year for scenarios with MAC catch-up campaigns
is primarily due to the incremental health systems costs of provid-
ing two doses of vaccine to five additional cohorts.4. Discussion
Our findings suggest that introducing HPV vaccination would be
cost-effective compared to no vaccination in Ghana in all scenarios6
evaluated. Further, bivalent vaccination with a campaign had
higher impact and lower cost and thus dominated the other sce-
narios. While Ghana does not currently have a prespecified thresh-
old for determining whether an intervention represents good value
and former WHO guidance suggesting thresholds of 1–3 times GDP
per capita are no longer recommended [33], recent econometric
modeling based on opportunity costs and income elasticity suggest
potential cost-effectiveness thresholds for Ghana of 4–40% GDP per
capita [34]. Our results suggest that national HPV vaccine introduc-
tion would be cost-effective under any scenario at willingness to
pay thresholds of at least 40% of the 2018 GDP per capita. At will-
ingness to pay thresholds lower than 40% of the 2018 GDP per cap-
Table 4
Cost per DALY averted for each scenario compared to no vaccination.
Target population Vaccine
selection
































CR: Credible range; DALY: Disability-adjusted life year.
* This strategy dominates all others in an incremental cost-effectiveness analysis.
E. Vodicka, J. Nonvignon, K.O. Antwi-Agyei et al. Vaccine xxx (xxxx) xxxita, the probability of cost-effectiveness is dependent on strategy
with bivalent vaccination via a MAC campaign followed by routine
immunization being the most favorable approach.
Inclusion of a one-time catch-up campaign is expected to create
greater value for money than routine immunization alone, but also
incur higher costs in the first year due to greater delivery costs. The
bivalent vaccination may generate better value than quadrivalent
due to relevant cross-protection against HPV types 31, 33 and 45,
which have been shown to be prevalent among 5.1%, 0.7% and
21.9% of cervical cancer cases in Ghana, respectively [24]. Impor-
tantly, economic evidence needs to be considered alongside




























Quadrivalent MAC + RI
GDP per capita
MAC: Mul-age cohort; RI: roune immuniza
Fig. 3. Cost-effectiveness acceptability curve from the societal perspective demonstr
thresholds.
7
jected that introducing national HPV vaccine program would cost
the MOH an average of $10.9-$15.4 M per year (undiscounted),
depending on the strategy. First-year costs were estimated to be
higher than subsequent years; this was particularly true for strate-
gies incorporating a one-time campaign among a MAC due to the
additional per-person delivery costs and health system costs asso-
ciated with vaccination of multiple cohorts.
In Ghana, the first-year undiscounted financial costs for delivery
to 9-year-old girls plus a one-time campaign among 10–14-year-
old girls to total over $54 M with either the bivalent or quadriva-
lent vaccine. While inclusion of a MAC in the first year would be
more cost-effective, the first-year financial costs represent approx-
imately 54% of projected annual costs for the total immunization
program based on cMYP estimates for 2022 which may limit the
budget feasibility of a MAC. This illustrates the difficult tradeoffs
and choices that governments in LMICs face between investing in
higher-value public health strategies and real-world budget con-
straints, even with subsidies and introduction support from exter-
nal partners like Gavi. As Ghana moves toward a transition out of
Gavi eligibility to become fully self-financing in the coming decade,
the country’s co-financing share of Gavi vaccine price per dose will
move from 32% to 100%. This may bring challenges of vaccine
affordability, and budget prioritization across the EPI portfolio will
be amplified. And the country is hardly alone. An analysis estimat-
ing the funding gap for immunization across 94 LMICs projected
that the delivery of full vaccine programs would lead to a routine
immunization funding gap of over $7 billion between 2016 and
2020 (USD 2010) [35]. New vaccines with similar efficacy as exist-
ing products coming to market at reportedly lower prices may sup-
port countries in reducing the budget impact of vaccine
procurement for introduction. Future research on vaccine financing
mechanisms and vaccine delivery may support more cost-efficient
allocation of resources. $1,500  $2,000  $2,500
o-Pay Threshold 
Curve, Societal Perspecve 
Bivalent RI only
Quadrivalent RI only
0.4 x GDP per capita
on.
ating likelihood of vaccine cost-effectiveness across varying willingness to pay
E. Vodicka, J. Nonvignon, K.O. Antwi-Agyei et al. Vaccine xxx (xxxx) xxxOur estimates of the cost-effectiveness of HPV vaccination are
similar to other estimates for Ghana presented as part of multi-
regional analyses in the literature. A study by Goldie et al on the
health and economic impact of vaccination against HPV 16 and
18 in 72 Gavi-eligible countries estimated a cost per DALY averted
of $310–$810 in Ghana (USD 2005) [18]. A second study by Jit et al
evaluating vaccine cost-effectiveness in 178 countries projected a
cost per DALY averted with HPV vaccination of $436 for vaccinat-
ing 12 year old girls (USD 2011) [36]. These findings are in line
with the cost-effectiveness ratios estimated in our study for each
scenario: $158–$494 per DALY averted from the government per-
spective and $152–$488 per DALY averted from the societal per-
spective (95% credible ranges of $19–$739 and $18–$733 from
government and societal perspectives, respectively).
This study has some limitations. First, proportionate outcomes
models are relatively simple and do not account for more compli-
cated health state transitions (i.e., progression and regression of
disease). However, they have the advantage of being transparent
and relatively easy to communicate. They have also been shown
to generate cost-effectiveness results consistent with more com-
plex models in low- and middle-income countries [36]. Second,
the model does not incorporate costs or disease burden associated
with prevention, detection, or treatment of pre-cancerous lesions,
which contribute to the overall cervical cancer burden of disease.
However, Ghana does not have a national cervical cancer screening
program and current screening rates are low [37]. Therefore, while
the model may underestimate the potential disease burden associ-
ated with pre-cancerous lesions, estimates of treatment costs likely
reflect the current care practice in Ghana with few women receiv-
ing screening and referral to treatment for early detection of pre-
cancerous lesions [37]. Additionally, the model does not consider
potential herd effects associated with HPV vaccine, although some
evidence of immunity in vaccinated groups may reduce the preva-
lence of vaccine-targeted HPV types among unvaccinated groups
[38–41]. While this analysis incorporates data on cross-
protection, recently published estimates find lower levels of
cross-protection relative to inputs in this analysis. This implies that
our impact estimates may be slight overestimates [42]. Finally,
while the model incorporates locally specific data on vaccine deliv-
ery and cervical cancer treatment costs, data on household level
costs to be included in the estimates were limited. Therefore, the
societal perspective is conservative and likely underestimates the
household level-costs associated cervical cancer care. Due to data
limitations, the probabilistic simulations utilized a PERT-Beta dis-
tribution for cost data instead of a Gamma or log-normal distribu-
tion. Despite the limitations, our findings were in line with global
projections of HPV vaccination cost-effectiveness and, to our
knowledge, is the first economic evaluation specific to Ghana that
incorporates non-vaccine type cross-protection and estimates the
financial implications of vaccine delivery strategies.
Evidence suggests that without significant and urgent scaling
up vaccination, screening and treatment, cervical cancer-related
deaths in LMICs could rise by up to 50% by 2040 [43]. Our findings
indicate that national introduction of HPV vaccination among girls
in Ghana would be a cost-effective approach to significantly reduce
the cervical-cancer related disease burden compared to no vacci-
nation. Importantly, economic evidence needs to be considered
alongside budget impact, affordability, feasibility, equity, and other
local considerations.5. Funding sources
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